Nocion Therapeutics, Inc. — SEC Form D Filing

Nocion Therapeutics, Inc. filed an SEC Form D on March 13, 2026, reporting $23.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
March 13, 2026
Amount reported
$23.00M
Round stage
Series B+
Industry
Pharmaceuticals
Website
https://www.nociontx.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Nocion Therapeutics addresses the need for effective treatment options for conditions arising from neurogenic inflammation, such as chronic cough, pain, and itch.

Solution

They are developing a new class of therapies called 'nocions' that target inflamed nociceptors, providing sustained relief without affecting non-pain sensory neurons.

Why now

Chronic cough and other conditions caused by neurogenic inflammation represent significant unmet medical needs with no proven standard of care.

Verdict

Investors backed Nocion Therapeutics because the promise of a new class of therapies offered a compelling narrative of addressing significant unmet medical needs, not merely an incremental improvement over existing pain relief solutions. Implicitly, they bet on the regulatory pathway to approval for 'nocions' and the potential to carve out a unique position in a crowded pain management space. However, the limited upside lies in the traditional reliance on the safety and efficacy of new therapeutic approaches, which may face skepticism and market resistance despite groundbreaking claims.

Source: SEC EDGAR Form D filing